A virtual care team consisting of physicians and pharmacists improved the adoption of life-saving therapies in patients with heart failure, leading to increased use of evidence-based treatments and better patient outcomes. The strategy was safe and effective, with comparable length of stay and safety events between the groups.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
A systematic review of 18 studies found that muscle relaxants and non-steroidal anti-inflammatory drugs (NSAIDs) can effectively reduce symptoms. Combining NSAIDs with paracetamol showed a greater improvement than using NSAIDs alone.
A groundbreaking study found that a new TB treatment strategy can shorten treatment duration while maintaining effectiveness. The TRUNCATE-TB trial showed that an initial 8-week treatment period followed by retreatment for those not cured was as effective as the standard 6-month treatment but halved the average total time on treatment.
Researchers at VCU Massey Cancer Center have discovered a novel combination therapy that dramatically suppresses the growth of AML cells, including those resistant to venetoclax. The dual mTORC1/2 inhibitors synergistically enhance AML cell death when paired with venetoclax.
A study found that immune checkpoint inhibitors enhance chemotherapy-induced neuropathic pain by blocking interaction between macrophages and neurons via PD1-PDL1 synergy. This discovery could lead to the development of therapeutic alternatives to prevent pain while maintaining anti-neoplastic effects.
Scientists at MIT have designed a novel nanoparticle platform that can deliver optimal ratios of multiple cancer drugs, leading to enhanced efficacy and reduced side effects. The bottlebrush-shaped particles can be loaded with varying concentrations of drugs, enabling the precise delivery of synergistic combinations.
A combination of two novel immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer. The study found that 23% of patients had a tumor reduction, and the disease control rate was 76%. The treatment was well-tolerated, but adverse events were common.
Researchers discovered a drug combination that targets immune evasion pathways in MYC amplified Medulloblastoma, a fatal childhood brain cancer. The treatment uses epigenetic drugs to unblock 'don't eat me' pathways and make tumors more appealing to macrophages.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
A new multidrug treatment combining pembrolizumab and all-trans retinoic acid has proven effective in treating stage IV melanoma, with an overall response rate of 71% and a one-year overall survival rate of 80%. The study's results are promising for patients who have failed traditional immunotherapy.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
A large registry-based study found lisdexamfetamine to be associated with the lowest risk of hospitalisation and death in people with amphetamine addiction. The medication showed a significant reduction in hospitalisation due to substance use disorder and any cause or death, while benzodiazepine and antidepressant use were linked to po...
Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
A new drug combination of cefepime and enmetazobactam has been found to be more effective in treating complicated urinary tract infections and acute pyelonephritis than a standard treatment. The study showed that the new combination was successful in treating 79% of patients, compared to 58.9% for the conventional treatment.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
A polypill combining blood pressure lowering agents, statins, and aspirin could avoid millions of premature deaths and cardiovascular disease cases annually. Its widespread availability would be affordable for most people globally, reducing CVD risk substantially.
A recent study analyzed the records of over 33,000 dementia patients in Wales and found that those closest to their diagnosis were taking an average of three or more medications. This suggests a possible link between polypharmacy and the development of dementia.
A new, shorter combination treatment has been shown to be effective in treating visceral leishmaniasis in Eastern Africa. The treatment, which combines miltefosine and paromomycin, is safer and reduces hospitalization time by 18%, eliminating the need for painful daily injections.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Using artificial intelligence, researchers from Tufts University have devised rules for faster and more effective identification of potential new drug cocktails against tuberculosis. The study developed a set of design principles to assemble drug combinations, reducing the amount of testing needed before moving to further study.
A new poll reveals that nearly half of people over 50 experience joint pain, and many turn to prescription-based treatments despite potential health risks. The poll's authors stress the need for healthcare providers to discuss medication interactions and non-drug options with patients.
A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.
A prespecified subgroup analysis of East Asian adults with lupus nephritis found that belimumab added to standard therapy improved kidney outcomes significantly. The study also showed no new safety concerns were raised in the subgroup.
Researchers discovered that combining a new target with an old chemotherapy drug can reduce resistance and potentially improve treatment outcomes for small cell lung cancer. The study used mouse models to show that inhibiting a protein called SMYD3, along with cyclophosphamide, stopped tumors in their tracks.
Researchers found that certain hepatitis C medications, such as glecaprevir and pibrentasvir, improved PTSD symptoms in a national cohort of VA patients. The study suggests these medications could fill the gap in FDA-approved treatments for PTSD, offering new hope for US adults affected by this condition.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
The study found that metformin lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent. Metformin also showed a significant reduction in serious outcomes when prescribed early in the onset of symptoms.
A new analysis shows that combining two anti-platelet drugs can reduce the risk of graft failure after coronary artery bypass surgery, but also increase the risk of bleeding. The study found a significant reduction in graft failure rates with dual therapy, but more bleeding events requiring medical attention.
A new mathematical framework predicts the most effective combinations of drugs to treat postmenopausal bone loss in patients. The model identifies optimal orderings that boost bone density and reduce long-term bone loss, improving treatment outcomes.
Researchers found that combining baricitinib with remdesivir and dexamethasone reduced the risk of death among patients hospitalized with severe COVID-19 pneumonia. However, the therapy was not associated with a reduction in ventilator time or hospital stay.
Researchers have found a promising new combination therapy that uses immunotherapy alongside a drug blocking a common gene mutation in lung cancer. The study suggests this combination may be effective in 'immune hot' tumours, which are more likely to respond.
Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...
Researchers have discovered eight potential leukemia-killing compounds that target mitochondria, inducing mitophagy to weaken cancer cells. The compounds showed significant synergy with existing chemotherapy drugs, offering a deadly one-two punch against leukemia.
Researchers at LSU Health Sciences Center have discovered a novel combination therapy that effectively treats chemo-resistant triple-negative breast cancer. The treatment combines two existing FDA-approved drugs, ceritinib and enzalutamide, to target the growth of cancer cells, showing promise for improving treatment outcomes.
A joint study by Finnish and US researchers has found a new combination of drugs that is effective against T-acute leukaemia, with temsirolimus and dasatinib showing enhanced synergistic effect. The therapy has shown promise in eradicating leukaemia cells in zebrafish and human disease.
Researchers at Ohio State University created a mathematical model that assesses the efficacy of immunomodulatory drugs in treating myocardial infarctions. The study found that certain combinations of these drug inhibitors were more efficient at reducing inflammation, offering new possibilities for improving patient outcomes.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
A combination of ramucirumab and pembrolizumab reduced the risk of death by 31% compared to standard care in advanced non-small cell lung cancer patients who had previously failed immunotherapy. The study found that these patients lived significantly longer, with a mean overall survival time of 14.6 months.
A study of over 4 million pregnancies found that exposure to valproate and topiramate during pregnancy doubles the risk of autism and intellectual disability in children. The largest such study confirms previous findings and highlights the need for informed decision-making on treatment options.
Nemvaleukin alfa, a new immunotherapy drug, has shown potential in treating late-stage cancers. The drug, used alone or in combination with pembrolizumab, stopped tumor growth or resulted in shrinkage for some patients with advanced kidney and melanoma cancers.
A global study found a combination of two drugs dramatically reduces the chances of suffering an asthma attack. The combination of albuterol and budesonide lowers the number of sudden episodes of shortness of breath, wheezing, and coughing in patients.
Researchers developed an algorithm to quickly identify two cancer drugs that work well together, reducing testing time from three years to eight weeks. The new method uses gene expression data to prioritize potential combinations and has been confirmed in lab tests.
A study published in Med found that the human microbiome's variation explains different patient responses to statins. The researchers discovered a Bacteroides enriched microbiome with lower diversity was associated with stronger LDL-lowering effects but greater disruption of blood glucose levels.
Researchers at the University of Waterloo found that combining diuretics and renin-angiotensin system inhibitors with ibuprofen can lead to acute kidney injury in people with certain medical profiles. The combination may be a 'triple whammy' that exacerbates dehydration, which is a major factor in acute kidney injury.
A study found that regular pharmacist visits reduced medicine-related problems by 60% and improved cognition scores. The research highlights the need for personalized pharmaceutical support within the aged-care sector to prevent harm from medicines.
Researchers developed a deep learning-based model to predict drug-drug interactions using gene expression data. The DeSIDE-DDI model can identify potentially dangerous pairs and act as a drug safety monitoring system, helping establish the correct usage of drugs in the development phase.
Canadian and German researchers have identified personalized prescriptions that combine drugs to treat obesity and Type 2 diabetes. The combination therapy shows higher effectiveness in some patients and fewer side effects compared to single drugs. Studies are now needed to understand why individuals respond differently to the treatment.
A new combination of ulipristal acetate and meloxicam has emerged as a promising candidate for an on-demand contraceptive pill. The study found that the combination disrupted ovulation in 89% of women, with treatment cycles being around 3 days longer than baseline cycles.
A Canadian study of over 12,000 hospital admissions found that updated product label changes did not reduce rates of accidental acetaminophen overdose. The study suggests additional measures are needed to prevent these episodes beyond just labeling changes.
A new study found that Black kidney transplant recipients exhibit a faster clearance rate of tacrolimus, an immunosuppressive drug. The study suggests that considering both sex and race when dosing tacrolimus may reduce adverse effects and enhance transplant outcomes.
Researchers developed a bioinformatics platform called REFLECT to predict optimal combination therapies based on co-occurring tumor alterations. The tool selected combinations that resulted in improved patient outcomes across pre-clinical and clinical studies, leading to increased durable responses.
Researchers developed an AI model to predict side effects from new combination therapies by analyzing over 15 million records of adverse events. The model can recognize patterns between drugs and their side effects, enabling the prediction of adverse events for individual therapy profiles.
A new therapy combination of immunotherapy, chemotherapy and an anti-inflammatory drug may improve immune response in patients with muscle-invasive bladder cancer. The treatment activates cells to fight tumor growth, potentially leading to better outcomes for patients who don't respond to current treatments.
Researchers have developed a new compound that prevents and treats COVID-19 caused by the Delta variant in mice. The compound, N-0385, blocks entry at the cell surface without causing detectable cell damage.
Researchers developed an AI method to analyze electronic health record data and predict optimal drug regimens for type 2 diabetes patients with similar characteristics. The algorithm successfully supported medication selection for over 83% of patients, leading to better management of the disease and improved patient engagement.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.